1
|
Fratz-Berilla EJ, Kohnhorst C, Trunfio N, Bush X, Gyorgypal A, Agarabi C. Evaluation of single-use optical and electrochemical pH sensors in upstream bioprocessing. Heliyon 2024; 10:e25512. [PMID: 38371965 PMCID: PMC10873650 DOI: 10.1016/j.heliyon.2024.e25512] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/08/2024] [Revised: 01/22/2024] [Accepted: 01/29/2024] [Indexed: 02/20/2024] Open
Abstract
Culture pH is a critical process parameter during CHO cell bioreactor operations that is key for proper cell growth, protein production, and maintaining the critical quality attributes of a monoclonal antibody drug substance. The traditional means of measuring pH in bioreactors is with an electrochemical probe that can withstand and maintain accuracy through repeated sterilization cycles. An alternative technique for measuring pH is an optical sensor composed of a fluorescent dye that is sensitive to the hydrogen ion concentration. In this work we explore single-use electrochemical and single-use optical pH sensors in stirred-tank and rocking bioreactors, respectively, to understand how their overall performance compares to traditional electrochemical probes in benchtop glass stirred tank bioreactors. We found that the single-use optical pH sensors were generally less accurate than the electrochemical probes, especially in detecting large pH drifts from the setpoint. The single-use electrochemical probes were increasingly accurate as pH was increased from <7.0 to 7.5 but tended to decrease in accuracy as the batch age increased. In conclusion, single-use pH sensors offer a convenient means to measure pH during an upstream bioprocess, but the limitations of these sensors should be built into process control such that deviations in process pH, and consequently potential fluctuations in product quality, can be avoided.
Collapse
Affiliation(s)
- Erica J. Fratz-Berilla
- U.S. Food and Drug Administration, Center for Drug Evaluation and Research, Office of Pharmaceutical Quality, Office of Biotechnology Products, Division of Biotechnology Review and Research II, Silver Spring, MD, USA
| | - Casey Kohnhorst
- U.S. Food and Drug Administration, Center for Drug Evaluation and Research, Office of Pharmaceutical Quality, Office of Biotechnology Products, Division of Biotechnology Review and Research II, Silver Spring, MD, USA
| | - Nicholas Trunfio
- U.S. Food and Drug Administration, Center for Drug Evaluation and Research, Office of Pharmaceutical Quality, Office of Biotechnology Products, Division of Biotechnology Review and Research II, Silver Spring, MD, USA
| | - Xin Bush
- U.S. Food and Drug Administration, Center for Drug Evaluation and Research, Office of Pharmaceutical Quality, Office of Biotechnology Products, Division of Biotechnology Review and Research II, Silver Spring, MD, USA
- Department of Biomedical and Pharmaceutical Sciences, College of Pharmacy, University of Rhode Island, Kingston, RI, USA
| | - Aron Gyorgypal
- Department of Chemical and Biochemical Engineering, School of Engineering, Rutgers the State University of New Jersey, Piscataway, NJ, 08854, USA
| | - Cyrus Agarabi
- U.S. Food and Drug Administration, Center for Drug Evaluation and Research, Office of Pharmaceutical Quality, Office of Biotechnology Products, Division of Biotechnology Review and Research II, Silver Spring, MD, USA
| |
Collapse
|
2
|
Li Z, Du X, Wang YMC. A survey of FDA Approved Monoclonal Antibodies and Fc-fusion Proteins for Manufacturing Changes and Comparability Assessment. Pharm Res 2024; 41:13-27. [PMID: 37910341 DOI: 10.1007/s11095-023-03627-5] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/07/2023] [Accepted: 10/16/2023] [Indexed: 11/03/2023]
Abstract
OBJECTIVE Manufacturing changes occur commonly throughout stages of biologics development and may result in product quality attribute changes. As changes in critical quality attributes have the potential to affect clinical safety and efficacy of products, it is imperative to ensure the quality and clinical performance before introducing the after-change products. Thus, we embarked on this project to understand what data have supported the manufacturing changes for licensed products with pre- and post-approval changes. METHODS We surveyed the manufacturing changes of 85 monoclonal antibodies and 10 Fc fusion proteins approved by the Food and Drug Administration as of December 25, 2021. After collecting the type and timing of changes for these products, we investigated the approaches that provided supporting data for the changes. The source documents included reports submitted by applicants and FDA's regulatory reviews. RESULTS Analytical comparability was assessed to support all identified manufacturing changes. Supporting clinical data were available in 92% of these manufacturing changes; including data from pharmacokinetic comparability studies alone (3%), other studies on efficacy or safety (70%) and a combination of both (19%). Clinical pharmacokinetic comparability data contributed to supporting substantial changes, such as host cell type or master cell bank changes, concentration or formulation changes, and changes from pre-filled syringes to autoinjectors, especially when introduced after completing pivotal studies. CONCLUSION Our comprehensive retrospective analysis provides an understanding of the regulatory experience and industry practice, which could facilitate developing appropriate comparability approaches to support manufacturing changes in the future.
Collapse
Affiliation(s)
- Zhe Li
- Office of Clinical Pharmacology, Center for Drug Evaluation and Research, U.S. Food and Drug Administration (OCP/CDER/FDA), 10903 New Hampshire Avenue, Silver Spring, MD, USA.
| | - Xiulian Du
- Office of Clinical Pharmacology, Center for Drug Evaluation and Research, U.S. Food and Drug Administration (OCP/CDER/FDA), 10903 New Hampshire Avenue, Silver Spring, MD, USA
| | - Yow-Ming C Wang
- Office of Clinical Pharmacology, Center for Drug Evaluation and Research, U.S. Food and Drug Administration (OCP/CDER/FDA), 10903 New Hampshire Avenue, Silver Spring, MD, USA
| |
Collapse
|
3
|
Schwarz H, Mäkinen ME, Castan A, Chotteau V. Monitoring of Amino Acids and Antibody N-Glycosylation in High Cell Density Perfusion Culture based on Raman Spectroscopy. Biochem Eng J 2022. [DOI: 10.1016/j.bej.2022.108426] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/02/2023]
|
4
|
Wilder LM, Thompson JR, Crooks RM. Electrochemical pH regulation in droplet microfluidics. LAB ON A CHIP 2022; 22:632-640. [PMID: 35018955 DOI: 10.1039/d1lc00952d] [Citation(s) in RCA: 2] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 06/14/2023]
Abstract
We report a method for electrochemical pH regulation in microdroplets generated in a microfluidic device. The key finding is that controlled quantities of reagents can be generated electrochemically in moving microdroplets confined within a microfluidic channel. Additionally, products generated at the anode and cathode can be isolated within descendant microdroplets. Specifically, ∼5 nL water-in-oil microdroplets are produced at a T-junction and then later split into two descendant droplets. During splitting, floor-patterned microelectrodes drive water electrolysis within the aqueous microdroplets to produce H+ and OH-. This results in a change in the pHs of the descendant droplets. The droplet pH can be regulated over a range of 5.9 to 7.7 by injecting controlled amounts of charge into the droplets. When the injected charge is between -6.3 and 54.5 nC nL-1, the measured pH of the resulting droplets is within ±0.1 pH units of that predicted based on the magnitude of the injected charge. This technique can likely be adapted to electrogeneration of other reagents within microdroplets.
Collapse
Affiliation(s)
- Logan M Wilder
- Department of Chemistry and the Texas Materials Institute, The University of Texas at Austin, 105 E. 24th Street, Stop A5300, Austin, Texas 78712-1224, USA.
| | - Jonathan R Thompson
- Department of Chemistry and the Texas Materials Institute, The University of Texas at Austin, 105 E. 24th Street, Stop A5300, Austin, Texas 78712-1224, USA.
| | - Richard M Crooks
- Department of Chemistry and the Texas Materials Institute, The University of Texas at Austin, 105 E. 24th Street, Stop A5300, Austin, Texas 78712-1224, USA.
| |
Collapse
|
5
|
Wiegmann V, Gardner RA, Spencer DIR, Baganz F. Equal mixing time enables scale-down and optimization of a CHO cell culture process using a shaken microbioreactor system. Biotechnol J 2021; 16:e2100360. [PMID: 34494367 DOI: 10.1002/biot.202100360] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/11/2021] [Revised: 09/03/2021] [Accepted: 09/03/2021] [Indexed: 11/07/2022]
Abstract
The advancement of microbioreactor technology in recent years has transformed early- and mid-stage process development. The monitoring and control capabilities of microbioreactors not only promote the quick accumulation of process knowledge but has also led to an increased scalability when compared to traditionally used systems such as shake flasks and microtitre plates. This study seeks to establish a framework for the micro-Matrix microbioreactor (Applikon-Biotechnology BV) as process development tool. Using the Dual Indicator System for Mixing Time, the system was initially characterized for mixing properties at varying operating conditions, which was found to yield mixing times between 0.9 and 41.8 s. A matched mixing time was proposed as scale-down criterion for an IgG4 producing GS-CHO fed-batch process between a 5 L stirred tank reactor (STR) and the micro-Matrix microbioreactor. Growth trends, maximum viable cell concentrations, final titre, and glycoprofiles were nearly identical at both scales. The scale-down model was then employed to optimize a bolus feeding regime using response surface methodology, which led to a 25.4% increase of the space-time yield and a 25% increase of the final titre. The optimized feeding strategy was validated at the small-scale and successfully scaled up to the 5 L STR. This work for the first time provides a framework of how the micro-Matrix microbioreactor can be implemented in a bioprocess development workflow and demonstrates scalability of growth and production kinetics as well as IgG4 glycosylation between the micro-Matrix and a benchtop-scale STR system.
Collapse
Affiliation(s)
- Vincent Wiegmann
- The Advanced Centre for Biochemical Engineering, Department of Biochemical Engineering, University College London, Gordon Street, London, WC1E 6BT, UK
| | | | | | - Frank Baganz
- The Advanced Centre for Biochemical Engineering, Department of Biochemical Engineering, University College London, Gordon Street, London, WC1E 6BT, UK
| |
Collapse
|
6
|
Särnlund S, Jiang Y, Chotteau V. Process intensification to produce a difficult-to-express therapeutic enzyme by high cell density perfusion or enhanced fed-batch. Biotechnol Bioeng 2021; 118:3533-3544. [PMID: 33914903 DOI: 10.1002/bit.27806] [Citation(s) in RCA: 3] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/30/2020] [Revised: 03/01/2021] [Accepted: 04/19/2021] [Indexed: 01/03/2023]
Abstract
Intensified bioprocesses have caught industrial interest in the field of biomanufacturing in recent years. Thanks to new technology, intensified processes can support high cell densities, higher productivities and longer process times, which together can offer lower cost of goods. In this study two different intensified process modes, high cell density perfusion and enhanced fed-batch, were evaluated and compared with a conventional fed-batch process for a difficult-to-express therapeutic enzyme. The intensified process modes were cultivated with a target cell density of 100 × 106 cells/ml and with alternating tangential flow filtration, ATF, as cell retention device. The processes were designed to resemble an established optimized fed-batch process using the knowledge of this process without new dedicated optimization for the intensified modes. The design strategy included decision of the ratio of feed concentrate to base medium and glucose supplementation, which were based on target cell-specific consumption rates of key amino acids and glucose, using a targeted feeding approach (TAFE). A difficult-to-express therapeutic enzyme with multiple glycosylation sites was expressed and analyzed in the different production processes. The two new intensified processes both achieved 10 times higher volumetric productivity (mg/L/day) with retained protein quality and minor changes to the glycan profile compared to the fed-batch process. The study demonstrates the potential of using intensified processes for sensitive complex enzymes. It is shown here that it is possible to transfer a developed fed-batch process into high cell density processes either in intensified fed-batch or steady-state perfusion without new dedicated optimization. The results demonstrated as well that these intensified modes significantly increase the productivity while maintaining the desired product quality, for instance the same amount of product was obtained in 1 day during the perfusion process than in a whole fed-batch run. Without any prior optimization of the perfusion rate, the high cell density perfusion process resulted in only 1.2 times higher medium cost per gram produced protein.
Collapse
Affiliation(s)
- Sigrid Särnlund
- Manufacturing Science and Technology, Swedish Orphan Biovitrum, Solna, Sweden.,AdBIOPRO, Competence Centre for Advanced Bioproduction by Continuous Processing, Stockholm, Sweden.,Department of Industrial Biotechnology, School of Engineering Sciences in Chemistry, Biotechnology and Health, Royal Institute of Technology, Stockholm, Sweden
| | - Yun Jiang
- Manufacturing Science and Technology, Swedish Orphan Biovitrum, Solna, Sweden
| | - Veronique Chotteau
- AdBIOPRO, Competence Centre for Advanced Bioproduction by Continuous Processing, Stockholm, Sweden.,Department of Industrial Biotechnology, School of Engineering Sciences in Chemistry, Biotechnology and Health, Royal Institute of Technology, Stockholm, Sweden
| |
Collapse
|
7
|
Kaur H. Characterization of glycosylation in monoclonal antibodies and its importance in therapeutic antibody development. Crit Rev Biotechnol 2021; 41:300-315. [PMID: 33430641 DOI: 10.1080/07388551.2020.1869684] [Citation(s) in RCA: 33] [Impact Index Per Article: 11.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/06/2023]
Abstract
Glycosylation is one of the structurally diverse and complex forms of post translational modifications observed in proteins which influence the effector functions of IgG-Fc. Although the glycosylation constitutes 2-3% of the total mass of the IgG antibody, a thorough assessment of glycoform distribution present on the antibody is a critical quality attribute (cQA) for the majority of novel and biosimilar monoclonal antibody (mAb) development. This review paper will highlight the impact of different glycoforms such as galactose, fucose, high mannose, NANA (N-acetylneuraminic acid), and NGNA (N-glycoylneuraminic acid) on the safety/immunogeneicity, efficacy/biological activity and clearance (pharmacodynamics/pharmacokinetic property (PD/PK)) of biological molecules. In addition, this paper will summarize routinely employed reliable analytical techniques such as hydrophilic interaction chromatography (HILIC), high performance anion exchange chromatography with pulsed amperometric detection (HPAEC-PAD) and mass spectrometry (MS) for characterizing and monitoring glycosylation in monoclonal antibodies (mAbs). The advantages and disadvantages of each of the methods are addressed. The scope of this review paper is limited to only N-linked and O-linked glycosylation.
Collapse
Affiliation(s)
- Harleen Kaur
- Analytical Sciences, Aurobindo Biologics, Hyderabad, India
| |
Collapse
|
8
|
Abstract
Glycosylation is a common posttranslational modification of therapeutic proteins. The glycosylation pattern is dependent on many parameters such as the host cell line or the culture conditions. N- and O-linked glycans usually play a great role on the stability, safety, and efficacy of the drug. For this reason, glycosylation is considered as a critical quality attribute of therapeutic glycoproteins, and a thorough characterization should be performed, as well as a systematic control for each batch produced. This chapter gives a short presentation of the structure of glycans commonly found on recombinant therapeutic proteins, and their role on the properties of the drug, in terms of stability, pharmacokinetics, safety, and efficacy. Lastly, the use of mass spectrometry for the analysis of glycoproteins is briefly described.
Collapse
|
9
|
Stringhini M, Mock J, Fontana V, Murer P, Neri D. Antibody-mediated delivery of LIGHT to the tumor boosts natural killer cells and delays tumor progression. MAbs 2021; 13:1868066. [PMID: 33404287 PMCID: PMC7808322 DOI: 10.1080/19420862.2020.1868066] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/08/2020] [Revised: 12/15/2020] [Accepted: 12/18/2020] [Indexed: 11/05/2022] Open
Abstract
LIGHT is a member of the tumor necrosis factor superfamily, which has been claimed to mediate anti-tumor activity on the basis of cancer cures observed in immunocompetent mice bearing transgenic LIGHT-expressing tumors. The preclinical development of a LIGHT-based therapeutic has been hindered by the lack of functional stability exhibited by this protein. Here, we describe the cloning, expression, and characterization of five antibody-LIGHT fusion proteins, directed against the alternatively spliced extra domain A of fibronectin, a conserved tumor-associated antigen. Among the five tested formats, only the sequential fusion of the F8 antibody in single-chain diabody format, followed by the LIGHT homotrimer expressed as a single polypeptide, yielded a protein (termed "F8-LIGHT") that was not prone to aggregation. A quantitative biodistribution analysis in tumor-bearing mice, using radio-iodinated protein preparations, confirmed that F8-LIGHT was able to preferentially accumulate at the tumor site, with a tumor-to-blood ratio of ca. five to one 24 hours after intravenous administration. Tumor therapy experiments, performed in two murine tumor models (CT26 and WEHI-164), featuring different levels of lymphocyte infiltration into the neoplastic mass, revealed that F8-LIGHT could significantly reduce tumor-cell growth and was more potent than a similar fusion protein (KSF-LIGHT), directed against hen egg lysozyme and serving as negative control of irrelevant specificity in the mouse. At a mechanistic level, the activity of F8-LIGHT was mainly due to an intratumoral expansion of natural killer cells, whereas there was no evidence of expansion of CD8 + T cells, neither in the tumor, nor in draining lymph nodes. Abbreviations: CTLA-4: Cytotoxic T-lymphocytes-associated protein 4; EGFR: Epidermal growth factor receptor; HVEM: Herpesvirus entry mediator; IFNγ: Interferon-gamma; LIGHT: Lymphotoxin, exhibits inducible expression and competes with HSV glycoprotein D for binding to herpesvirus entry mediator, a receptor expressed on T lymphocytes; LTβR: Lymphotoxin beta receptor; NF-κB: Nuclear factor "kappa-light-chain-enhancer" of activated B cells; NK: Natural killer cells; PD-1: Programmed cell death protein 1; PD-L1: Programmed death-ligand 1; TNF: Tumor necrosis factor.
Collapse
MESH Headings
- Animals
- Antibodies, Monoclonal, Humanized/genetics
- Antibodies, Monoclonal, Humanized/immunology
- Antibodies, Monoclonal, Humanized/metabolism
- CHO Cells
- Cell Line, Tumor
- Cricetinae
- Cricetulus
- Disease Progression
- Humans
- Killer Cells, Natural/drug effects
- Killer Cells, Natural/immunology
- Lymphocyte Activation/drug effects
- Lymphocyte Activation/immunology
- Mice, Inbred BALB C
- Neoplasms/drug therapy
- Neoplasms/immunology
- Neoplasms/metabolism
- Recombinant Fusion Proteins/immunology
- Recombinant Fusion Proteins/pharmacokinetics
- Recombinant Fusion Proteins/pharmacology
- Tissue Distribution
- Tumor Burden/drug effects
- Tumor Burden/immunology
- Tumor Necrosis Factor Ligand Superfamily Member 14/genetics
- Tumor Necrosis Factor Ligand Superfamily Member 14/immunology
- Tumor Necrosis Factor Ligand Superfamily Member 14/metabolism
- Mice
Collapse
Affiliation(s)
- Marco Stringhini
- Department of Chemistry and Applied Biosciences, Swiss Federal Institute of Technology (ETH Zürich), Zürich, Switzerland
| | - Jacqueline Mock
- Department of Chemistry and Applied Biosciences, Swiss Federal Institute of Technology (ETH Zürich), Zürich, Switzerland
| | - Vanessa Fontana
- Department of Chemistry and Applied Biosciences, Swiss Federal Institute of Technology (ETH Zürich), Zürich, Switzerland
| | - Patrizia Murer
- Department of Chemistry and Applied Biosciences, Swiss Federal Institute of Technology (ETH Zürich), Zürich, Switzerland
| | - Dario Neri
- Department of Chemistry and Applied Biosciences, Swiss Federal Institute of Technology (ETH Zürich), Zürich, Switzerland
| |
Collapse
|
10
|
van der Horst HJ, Nijhof IS, Mutis T, Chamuleau MED. Fc-Engineered Antibodies with Enhanced Fc-Effector Function for the Treatment of B-Cell Malignancies. Cancers (Basel) 2020; 12:E3041. [PMID: 33086644 PMCID: PMC7603375 DOI: 10.3390/cancers12103041] [Citation(s) in RCA: 34] [Impact Index Per Article: 8.5] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/21/2020] [Revised: 10/12/2020] [Accepted: 10/14/2020] [Indexed: 11/17/2022] Open
Abstract
Monoclonal antibody (mAb) therapy has rapidly changed the field of cancer therapy. In 1997, the CD20-targeting mAb rituximab was the first mAb to be approved by the U.S. Food and Drug Administration (FDA) for treatment of cancer. Within two decades, dozens of mAbs entered the clinic for treatment of several hematological cancers and solid tumors, and numerous more are under clinical investigation. The success of mAbs as cancer therapeutics lies in their ability to induce various cytotoxic machineries against specific targets. These cytotoxic machineries include antibody-dependent cellular cytotoxicity (ADCC), antibody-dependent cellular phagocytosis (ADCP), and complement-dependent cytotoxicity (CDC), which are all mediated via the fragment crystallizable (Fc) domain of mAbs. In this review article, we will outline the novel approaches of engineering these Fc domains of mAbs to enhance their Fc-effector function and thereby their anti-tumor potency, with specific focus to summarize their (pre-) clinical status for the treatment of B-cell malignancies, including chronic lymphocytic leukemia (CLL), B-cell non-Hodgkin lymphoma (B-NHL), and multiple myeloma (MM).
Collapse
Affiliation(s)
- Hilma J. van der Horst
- Department of Hematology, Cancer Center Amsterdam, Amsterdam UMC, VU Medical Center, 1081 HV Amsterdam, The Netherlands; (I.S.N.); (T.M.); (M.E.D.C.)
| | | | | | | |
Collapse
|
11
|
Antibody glycosylation: impact on antibody drug characteristics and quality control. Appl Microbiol Biotechnol 2020; 104:1905-1914. [DOI: 10.1007/s00253-020-10368-7] [Citation(s) in RCA: 24] [Impact Index Per Article: 6.0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/26/2019] [Revised: 01/02/2020] [Accepted: 01/09/2020] [Indexed: 12/21/2022]
|
12
|
Tang H, Zhang X, Zhang W, Fan L, Wang H, Tan WS, Zhao L. Insight into the roles of tyrosine on rCHO cell performance in fed-batch cultures. Appl Microbiol Biotechnol 2019; 103:6483-6494. [PMID: 31190239 DOI: 10.1007/s00253-019-09921-w] [Citation(s) in RCA: 5] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/08/2019] [Revised: 05/11/2019] [Accepted: 05/15/2019] [Indexed: 12/01/2022]
Abstract
Tyrosine (Tyr), as one of the least soluble amino acids, is essential to monoclonal antibody (mAb) production in recombinant Chinese hamster ovary (rCHO) cell cultures since its roles on maintaining the specific productivity (qmAb) and avoiding Tyr sequence variants. To understand the effects of Tyr on cell performance and its underlying mechanisms, rCHO cell-producing mAbs were cultivated at various cumulative Tyr addition concentrations (0.6 to 5.5 mM) in fed-batch processes. Low Tyr concentrations gave a much lower peak viable cell density (VCD) during the growth phase and also induced rapid cell death and pH decrease during the production phase, resulting in a low efficient fed-batch process. Autophagy was initiated following the inhibition of mTOR under the Tyr starvation condition. Excessive autophagy subsequently induced autophagic cell death, which was found as the major type of cell death in this study. Additionally, the results obtained here demonstrate that the decrease in culture pH under the Tyr starvation condition was associated with the autophagy and such pH drop might be attributed to the lysosome acidification and cell lysis.
Collapse
Affiliation(s)
- Hongping Tang
- The State Key Laboratory of Bioreactor Engineering, East China University of Science and Technology, Shanghai, 200237, China
| | - Xintao Zhang
- The State Key Laboratory of Bioreactor Engineering, East China University of Science and Technology, Shanghai, 200237, China
| | - Weijian Zhang
- The State Key Laboratory of Bioreactor Engineering, East China University of Science and Technology, Shanghai, 200237, China
| | - Li Fan
- The State Key Laboratory of Bioreactor Engineering, East China University of Science and Technology, Shanghai, 200237, China
| | - Haibin Wang
- Zhejiang Hisun Pharmaceutical Co., Ltd., Fuyang, Zhejiang, 311404, Hangzhou, China
| | - Wen-Song Tan
- The State Key Laboratory of Bioreactor Engineering, East China University of Science and Technology, Shanghai, 200237, China.
| | - Liang Zhao
- The State Key Laboratory of Bioreactor Engineering, East China University of Science and Technology, Shanghai, 200237, China.
| |
Collapse
|
13
|
Ehret J, Zimmermann M, Eichhorn T, Zimmer A. Impact of cell culture media additives on IgG glycosylation produced in Chinese hamster ovary cells. Biotechnol Bioeng 2019; 116:816-830. [PMID: 30552760 PMCID: PMC6590254 DOI: 10.1002/bit.26904] [Citation(s) in RCA: 32] [Impact Index Per Article: 6.4] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/02/2018] [Revised: 11/12/2018] [Accepted: 12/14/2018] [Indexed: 01/07/2023]
Abstract
Glycosylation is a key critical quality attribute for monoclonal antibodies and other recombinant proteins because of its impact on effector mechanisms and half‐life. In this study, a variety of compounds were evaluated for their ability to modulate glycosylation profiles of recombinant monoclonal antibodies produced in Chinese hamster ovary cells. Compounds were supplemented into the cell culture feed of fed‐batch experiments performed with a CHO K1 and a CHO DG44 cell line expressing a recombinant immunoglobulin G1 (IgG1). Experiments were performed in spin tubes or the ambr®15 controlled bioreactor system, and the impact of the compounds at various concentrations was determined by monitoring the glycosylation profile of the IgG and cell culture parameters, such as viable cell density, viability, and titer. Results indicate that the highest impact on mannosylation was achieved through 15 µM kifunensine supplementation leading to an 85.8% increase in high‐mannose containing species. Fucosylation was reduced by 76.1% through addition of 800 µM 2‐F‐peracetyl fucose. An increase of 40.9% in galactosylated species was achieved through the addition of 120 mM galactose in combination with 48 µM manganese and 24 µM uridine. Furthermore, 6.9% increased sialylation was detected through the addition of 30 µM dexamethasone in combination with the same manganese, uridine, and galactose mixture used to increase total galactosylation. Further compounds or combinations of additives were also efficient at achieving a smaller overall glycosylation modulation, required, for instance, during the development of biosimilars. To the best of our knowledge, no evaluation of the efficacy of such a variety of compounds in the same cell culture system has been described. The studied cell culture media additives are efficient modulators of glycosylation and are thus a valuable tool to produce recombinant glycoproteins.
Collapse
Affiliation(s)
- Janike Ehret
- Merck Life Sciences, Upstream R&D, Darmstadt, Germany
| | - Martina Zimmermann
- Merck Life Sciences, Upstream R&D, Darmstadt, Germany.,Institute for Organic Chemistry and Biochemistry, Technische Universität Darmstadt, Darmstadt, Germany
| | | | - Aline Zimmer
- Merck Life Sciences, Upstream R&D, Darmstadt, Germany
| |
Collapse
|
14
|
Farré R, Almendros I, Montserrat JM, Gozal D, Navajas D. Gas Partial Pressure in Cultured Cells: Patho-Physiological Importance and Methodological Approaches. Front Physiol 2018; 9:1803. [PMID: 30618815 PMCID: PMC6300470 DOI: 10.3389/fphys.2018.01803] [Citation(s) in RCA: 15] [Impact Index Per Article: 2.5] [Reference Citation Analysis] [Abstract] [Key Words] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/26/2018] [Accepted: 11/29/2018] [Indexed: 12/19/2022] Open
Abstract
Gas partial pressures within the cell microenvironment are one of the key modulators of cell pathophysiology. Indeed, respiratory gases (O2 and CO2) are usually altered in respiratory diseases and gasotransmitters (CO, NO, H2S) have been proposed as potential therapeutic agents. Investigating the pathophysiology of respiratory diseases in vitro mandates that cultured cells are subjected to gas partial pressures similar to those experienced by each cell type in its native microenvironment. For instance, O2 partial pressures range from ∼13% in the arterial endothelium to values as low as 2-5% in cells of other healthy tissues and to less than 1% in solid tumor cells, clearly much lower values than those used in conventional cell culture research settings (∼19%). Moreover, actual cell O2 partial pressure in vivo changes with time, at considerably different timescales as illustrated by tumors, sleep apnea, or mechanical ventilation. Unfortunately, the conventional approach to modify gas concentrations at the above culture medium precludes the tight and exact control of intra-cellular gas levels to realistically mimic the natural cell microenvironment. Interestingly, well-controlled cellular application of gas partial pressures is currently possible through commercially available silicone-like material (PDMS) membranes, which are biocompatible and have a high permeability to gases. Cells are seeded on one side of the membrane and tailored gas concentrations are circulated on the other side of the membrane. Using thin membranes (50-100 μm) the value of gas concentration is instantaneously (<0.5 s) transmitted to the cell microenvironment. As PDMS is transparent, cells can be concurrently observed by conventional or advanced microscopy. This procedure can be implemented in specific-purpose microfluidic devices and in settings that do not require expensive or complex technologies, thus making the procedure readily implementable in any cell biology laboratory. This review describes the gas composition requirements for a cell culture in respiratory research, the limitations of current experimental settings, and also suggests new approaches to better control gas partial pressures in a cell culture.
Collapse
Affiliation(s)
- Ramon Farré
- Unitat de Biofísica i Bioenginyeria, Facultat de Medicina i Ciències de la Salut, Universitat de Barcelona, Barcelona, Spain
- CIBER de Enfermedades Respiratorias, Madrid, Spain
- Institut d’Investigacions Biomèdiques August Pi i Sunyer, Barcelona, Spain
| | - Isaac Almendros
- Unitat de Biofísica i Bioenginyeria, Facultat de Medicina i Ciències de la Salut, Universitat de Barcelona, Barcelona, Spain
- CIBER de Enfermedades Respiratorias, Madrid, Spain
- Institut d’Investigacions Biomèdiques August Pi i Sunyer, Barcelona, Spain
| | - Josep M. Montserrat
- CIBER de Enfermedades Respiratorias, Madrid, Spain
- Institut d’Investigacions Biomèdiques August Pi i Sunyer, Barcelona, Spain
- Sleep Lab, Hospital Clinic of Barcelona, Barcelona, Spain
| | - David Gozal
- Department of Child Health, University of Missouri School of Medicine, Columbia, MO, United States
| | - Daniel Navajas
- Unitat de Biofísica i Bioenginyeria, Facultat de Medicina i Ciències de la Salut, Universitat de Barcelona, Barcelona, Spain
- CIBER de Enfermedades Respiratorias, Madrid, Spain
- Institute for Bioengineering of Catalonia, Barcelona Institute of Science and Technology, Barcelona, Spain
| |
Collapse
|
15
|
Wolf MK, Lorenz V, Karst DJ, Souquet J, Broly H, Morbidelli M. Development of a shake tube‐based scale‐down model for perfusion cultures. Biotechnol Bioeng 2018; 115:2703-2713. [DOI: 10.1002/bit.26804] [Citation(s) in RCA: 27] [Impact Index Per Article: 4.5] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/28/2018] [Revised: 07/10/2018] [Accepted: 07/16/2018] [Indexed: 01/10/2023]
Affiliation(s)
- Moritz K.F. Wolf
- Department of Chemistry and Applied BiosciencesInstitute of Chemical and Bioengineering, ETH ZurichZurich Switzerland
| | - Veronika Lorenz
- Department of Chemistry and Applied BiosciencesInstitute of Chemical and Bioengineering, ETH ZurichZurich Switzerland
| | - Daniel J. Karst
- Department of Chemistry and Applied BiosciencesInstitute of Chemical and Bioengineering, ETH ZurichZurich Switzerland
| | - Jonathan Souquet
- Biotech Process Sciences, Merck BiopharmaCorsier‐sur‐Vevey Switzerland
| | - Hervé Broly
- Biotech Process Sciences, Merck BiopharmaCorsier‐sur‐Vevey Switzerland
| | - Massimo Morbidelli
- Department of Chemistry and Applied BiosciencesInstitute of Chemical and Bioengineering, ETH ZurichZurich Switzerland
| |
Collapse
|
16
|
Jiang R, Chen H, Xu S. pH excursions impact CHO cell culture performance and antibody N-linked glycosylation. Bioprocess Biosyst Eng 2018; 41:1731-1741. [DOI: 10.1007/s00449-018-1996-y] [Citation(s) in RCA: 20] [Impact Index Per Article: 3.3] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/08/2018] [Accepted: 07/30/2018] [Indexed: 10/28/2022]
|
17
|
Dionne B, Mishra N, Butler M. A low redox potential affects monoclonal antibody assembly and glycosylation in cell culture. J Biotechnol 2017; 246:71-80. [DOI: 10.1016/j.jbiotec.2017.01.016] [Citation(s) in RCA: 10] [Impact Index Per Article: 1.4] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/22/2016] [Revised: 01/08/2017] [Accepted: 01/27/2017] [Indexed: 11/29/2022]
|
18
|
Cell culture media supplementation of infrequently used sugars for the targeted shifting of protein glycosylation profiles. Biotechnol Prog 2017; 33:511-522. [DOI: 10.1002/btpr.2429] [Citation(s) in RCA: 12] [Impact Index Per Article: 1.7] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/31/2016] [Revised: 12/10/2016] [Indexed: 11/07/2022]
|
19
|
Fan Y, Kildegaard HF, Andersen MR. Engineer Medium and Feed for Modulating N-Glycosylation of Recombinant Protein Production in CHO Cell Culture. Methods Mol Biol 2017; 1603:209-226. [PMID: 28493133 DOI: 10.1007/978-1-4939-6972-2_14] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 06/07/2023]
Abstract
Chinese hamster ovary (CHO) cells have become the primary expression system for the production of complex recombinant proteins due to their long-term success in industrial scale production and generating appropriate protein N-glycans similar to that of humans. Control and optimization of protein N-glycosylation is crucial, as the structure of N-glycans can largely influence both biological and physicochemical properties of recombinant proteins. Protein N-glycosylation in CHO cell culture can be controlled and tuned by engineering medium, feed, culture process, as well as genetic elements of the cell. In this chapter, we will focus on how to carry out experiments for N-glycosylation modulation through medium and feed optimization. The workflow and typical methods involved in the experiment process will be presented.
Collapse
Affiliation(s)
- Yuzhou Fan
- Department of Systems Biology, Technical University of Denmark, Kgs. Lyngby, Denmark.
- The Novo Nordisk Foundation Center for Biosustainability, Technical University of Denmark, 2800 Kgs. Lyngby, Denmark.
| | - Helene Faustrup Kildegaard
- The Novo Nordisk Foundation Center for Biosustainability, Technical University of Denmark, 2800 Kgs. Lyngby, Denmark
| | | |
Collapse
|
20
|
Batra J, Rathore AS. Glycosylation of monoclonal antibody products: Current status and future prospects. Biotechnol Prog 2016; 32:1091-1102. [DOI: 10.1002/btpr.2366] [Citation(s) in RCA: 35] [Impact Index Per Article: 4.4] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/13/2016] [Revised: 09/04/2016] [Indexed: 12/31/2022]
Affiliation(s)
- Jyoti Batra
- Department of Chemical Engineering; Indian Institute of Technology; Hauz Khas New Delhi India
| | - Anurag S. Rathore
- Department of Chemical Engineering; Indian Institute of Technology; Hauz Khas New Delhi India
| |
Collapse
|
21
|
Monteil DT, Juvet V, Paz J, Moniatte M, Baldi L, Hacker DL, Wurm FM. A comparison of orbitally-shaken and stirred-tank bioreactors: pH modulation and bioreactor type affect CHO cell growth and protein glycosylation. Biotechnol Prog 2016; 32:1174-1180. [PMID: 27453130 DOI: 10.1002/btpr.2328] [Citation(s) in RCA: 16] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/15/2016] [Revised: 07/01/2016] [Indexed: 01/21/2023]
Abstract
Orbitally shaken bioreactors (OSRs) support the suspension cultivation of animal cells at volumetric scales up to 200 L and are a potential alternative to stirred-tank bioreactors (STRs) due to their rapid and homogeneous mixing and high oxygen transfer rate. In this study, a Chinese hamster ovary cell line producing a recombinant antibody was cultivated in a 5 L OSR and a 3 L STR, both operated with or without pH control. Effects of bioreactor type and pH control on cell growth and metabolism and on recombinant protein production and glycosylation were determined. In pH-controlled bioreactors, the glucose consumption and lactate production rates were higher relative to cultures grown in bioreactors without pH control. The cell density and viability were higher in the OSRs than in the STRs, either with or without pH control. Volumetric recombinant antibody yields were not affected by the process conditions, and a glycan analysis of the antibody by mass spectrometry did not reveal major process-dependent differences in the galactosylation index. The results demonstrated that OSRs are suitable for recombinant protein production from suspension-adapted animal cells. © 2016 American Institute of Chemical Engineers Biotechnol. Prog., 32:1174-1180, 2016.
Collapse
Affiliation(s)
- Dominique T Monteil
- Laboratory of Cellular Biotechnology (LBTC), École Polytechnique Fédérale De Lausanne (EPFL), Lausanne, CH-1015, Switzerland
| | - Valentin Juvet
- Laboratory of Cellular Biotechnology (LBTC), École Polytechnique Fédérale De Lausanne (EPFL), Lausanne, CH-1015, Switzerland
| | - Jonathan Paz
- Proteomics Core Facility (PCF), École Polytechnique Fédérale De Lausanne (EPFL), Lausanne, CH-1015, Switzerland
| | - Marc Moniatte
- Proteomics Core Facility (PCF), École Polytechnique Fédérale De Lausanne (EPFL), Lausanne, CH-1015, Switzerland
| | - Lucia Baldi
- Laboratory of Cellular Biotechnology (LBTC), École Polytechnique Fédérale De Lausanne (EPFL), Lausanne, CH-1015, Switzerland
| | - David L Hacker
- Laboratory of Cellular Biotechnology (LBTC), École Polytechnique Fédérale De Lausanne (EPFL), Lausanne, CH-1015, Switzerland.,Protein Expression Core Facility (PECF), École Polytechnique Fédérale De Lausanne (EPFL), Lausanne, CH-1015, Switzerland
| | - Florian M Wurm
- Laboratory of Cellular Biotechnology (LBTC), École Polytechnique Fédérale De Lausanne (EPFL), Lausanne, CH-1015, Switzerland.
| |
Collapse
|
22
|
Dorokhov YL, Sheshukova EV, Kosobokova EN, Shindyapina AV, Kosorukov VS, Komarova TV. Functional role of carbohydrate residues in human immunoglobulin G and therapeutic monoclonal antibodies. BIOCHEMISTRY (MOSCOW) 2016; 81:835-57. [DOI: 10.1134/s0006297916080058] [Citation(s) in RCA: 11] [Impact Index Per Article: 1.4] [Reference Citation Analysis] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 11/23/2022]
|
23
|
Liu H, Nowak C, Shao M, Ponniah G, Neill A. Impact of cell culture on recombinant monoclonal antibody product heterogeneity. Biotechnol Prog 2016; 32:1103-1112. [DOI: 10.1002/btpr.2327] [Citation(s) in RCA: 25] [Impact Index Per Article: 3.1] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/11/2016] [Revised: 07/19/2016] [Indexed: 12/20/2022]
Affiliation(s)
- Hongcheng Liu
- Product Characterization, Global Analytical and Pharmaceutical Development; Alexion Pharmaceuticals; CT06410 Cheshire
| | - Christine Nowak
- Product Characterization, Global Analytical and Pharmaceutical Development; Alexion Pharmaceuticals; CT06410 Cheshire
| | - Mei Shao
- Late Stage Upstream Development, Global Process Development; Alexion Pharmaceuticals; CT06410 Cheshire
| | - Gomathinayagam Ponniah
- Product Characterization, Global Analytical and Pharmaceutical Development; Alexion Pharmaceuticals; CT06410 Cheshire
| | - Alyssa Neill
- Product Characterization, Global Analytical and Pharmaceutical Development; Alexion Pharmaceuticals; CT06410 Cheshire
| |
Collapse
|
24
|
Xu S, Chen H. High-density mammalian cell cultures in stirred-tank bioreactor without external pH control. J Biotechnol 2016; 231:149-159. [DOI: 10.1016/j.jbiotec.2016.06.019] [Citation(s) in RCA: 76] [Impact Index Per Article: 9.5] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/19/2016] [Accepted: 06/14/2016] [Indexed: 01/02/2023]
|
25
|
St. Amand MM, Hayes J, Radhakrishnan D, Fernandez J, Meyer B, Robinson AS, Ogunnaike BA. Identifying a robust design space for glycosylation during monoclonal antibody production. Biotechnol Prog 2016; 32:1149-1162. [DOI: 10.1002/btpr.2316] [Citation(s) in RCA: 10] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/30/2016] [Revised: 05/08/2016] [Indexed: 12/17/2022]
Affiliation(s)
- Melissa M. St. Amand
- Dept. of Chemical and Biomolecular Engineering; University of Delaware; Newark DE 19716
| | - James Hayes
- Biopharm Process Development, GlaxoSmithKline; King of Prussia PA 19406
| | - Devesh Radhakrishnan
- Dept. of Chemical and Biomolecular Engineering; University of Delaware; Newark DE 19716
| | - Janice Fernandez
- Biopharm Process Development, GlaxoSmithKline; King of Prussia PA 19406
| | - Bill Meyer
- Biopharm Process Development, GlaxoSmithKline; King of Prussia PA 19406
| | - Anne S. Robinson
- Dept. of Chemical and Biomolecular Engineering; University of Delaware; Newark DE 19716
- Dept. of Chemical and Biomolecular Engineering; Tulane University; New Orleans LA 70118
| | | |
Collapse
|
26
|
Slade PG, Caspary RG, Nargund S, Huang CJ. Mannose metabolism in recombinant CHO cells and its effect on IgG glycosylation. Biotechnol Bioeng 2016; 113:1468-80. [PMID: 26724786 DOI: 10.1002/bit.25924] [Citation(s) in RCA: 32] [Impact Index Per Article: 4.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/05/2015] [Revised: 11/24/2015] [Accepted: 12/28/2015] [Indexed: 01/02/2023]
Abstract
Understanding the causes of high-mannose (HM) glycosylation of recombinant IgG in CHO cells would facilitate the production of therapeutics. CHO cells grown with mannose as the major carbon source demonstrated a dramatic increase in total HM glycosylation in recombinant IgG, with no effect on cell growth, viability, or titer. Quantitative metabolomics and (13) C flux analysis were used to explore the mechanism for increased HM glycosylation and understand the metabolism of mannose in CHO cells. It was demonstrated that mannose was a good carbon source for CHO cell growth and IgG production, readily entering both glycolysis and the TCA Cycle. Previous mechanisms for increased HM glycosylation during antibody production have been attributed to changes in pH, osmolality, increased specific productivity, and nutrient limitation. The results from this study propose a novel mechanism where an increased carbon flux in the GDP-mannose synthetic pathway increased the intracellular concentration of mannose-containing metabolites. The abnormally high concentration of mannose and mannose-metabolites were shown to inhibit α-mannosidase activity and it was proposed that this inhibition in the ER and Golgi caused the production of IgG with increased high-mannose glycosylation. Biotechnol. Bioeng. 2016;113: 1468-1480. © 2016 Wiley Periodicals, Inc.
Collapse
Affiliation(s)
- Peter G Slade
- Process and Product Development, Amgen Inc., 1201 Amgen Court West, Seattle, 98119, Washington.
| | - R Guy Caspary
- Process and Product Development, Amgen Inc., 1201 Amgen Court West, Seattle, 98119, Washington
| | - Shilpa Nargund
- Process and Product Development, Amgen Inc., Thousand Oaks, California
| | - Chung-Jr Huang
- Process and Product Development, Amgen Inc., Thousand Oaks, California
| |
Collapse
|
27
|
Wuhrer M, Selman MHJ, McDonnell LA, Kümpfel T, Derfuss T, Khademi M, Olsson T, Hohlfeld R, Meinl E, Krumbholz M. Pro-inflammatory pattern of IgG1 Fc glycosylation in multiple sclerosis cerebrospinal fluid. J Neuroinflammation 2015; 12:235. [PMID: 26683050 PMCID: PMC4683913 DOI: 10.1186/s12974-015-0450-1] [Citation(s) in RCA: 76] [Impact Index Per Article: 8.4] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/16/2015] [Accepted: 12/02/2015] [Indexed: 11/10/2022] Open
Abstract
BACKGROUND Immunoglobulin G (IgG) effector functions are regulated by the composition of glycans attached to a conserved N-glycosylation site in the Fc part. Intrathecal production of IgG, especially IgG1, is a hallmark of multiple sclerosis (MS), but nothing is known about IgG Fc glycosylation in MS and in cerebrospinal fluid (CSF) in general. METHODS We applied mass spectrometry of tryptic Fc glycopeptides to analyze IgG Fc glycosylation (sialylation, galactosylation, fucosylation, and bisecting N-acetylglucosamine (GlcNAc)) in 48 paired CSF and serum samples from adult patients with MS or a first demyelinating event highly suggestive of MS (designated as MS cases), and from healthy volunteers and patients with other non-inflammatory diseases (control group). p values were adjusted for multiple testing. RESULTS Our experiments revealed four main results. First, IgG1 glycosylation patterns were different in CSF vs. serum, in the MS group and even in control donors without intrathecal IgG synthesis. Second, in MS patients vs. controls, IgG1 glycosylation patterns were altered in CSF, but not in serum. Specifically, in CSF from the MS group, bisecting GlcNAc were elevated, and afucosylation and galactosylation were reduced. Elevated bisecting GlcNAc and reduced galactosylation are known to enhance IgG effector functions. Third, hypothesis-free regression analysis revealed that alterations of afucosylation and bisecting GlcNAc in CSF from MS cases peaked 2-3 months after the last relapse. Fourth, CSF IgG1 glycosylation correlated with the degree of intrathecal IgG synthesis and CSF cell count. CONCLUSIONS The CNS compartment as well as the inflammatory milieu in MS affect IgG1 Fc glycosylation. In MS, the CSF IgG1 glycosylation has features that enhance Fc effector functions.
Collapse
Affiliation(s)
- Manfred Wuhrer
- Center for Proteomics and Metabolomics, Leiden University Medical Center, Leiden, The Netherlands.
- Department of Molecular Cell Biology and Immunology, VU University Medical Center, Amsterdam, The Netherlands.
- Division of BioAnalytical Chemistry, VU University Amsterdam, Amsterdam, The Netherlands.
| | - Maurice H J Selman
- Center for Proteomics and Metabolomics, Leiden University Medical Center, Leiden, The Netherlands.
| | - Liam A McDonnell
- Center for Proteomics and Metabolomics, Leiden University Medical Center, Leiden, The Netherlands.
| | - Tania Kümpfel
- Institute of Clinical Neuroimmunology, Biomedical Center (BMC) and University Hospital, Campus Martinsried-Grosshadern, LMU Munich, Munich, Germany.
| | - Tobias Derfuss
- Departments of Neurology and Biomedicine, University Hospital, Basel, Switzerland.
| | - Mohsen Khademi
- Department of Clinical Neuroscience, Neuroimmunology Unit, Karolinska University Hospital, Stockholm, Sweden.
| | - Tomas Olsson
- Department of Clinical Neuroscience, Neuroimmunology Unit, Karolinska University Hospital, Stockholm, Sweden.
| | - Reinhard Hohlfeld
- Institute of Clinical Neuroimmunology, Biomedical Center (BMC) and University Hospital, Campus Martinsried-Grosshadern, LMU Munich, Munich, Germany.
- Munich Cluster of Systems Neurology (SyNergy), Munich, Germany.
| | - Edgar Meinl
- Institute of Clinical Neuroimmunology, Biomedical Center (BMC) and University Hospital, Campus Martinsried-Grosshadern, LMU Munich, Munich, Germany.
| | - Markus Krumbholz
- Institute of Clinical Neuroimmunology, Biomedical Center (BMC) and University Hospital, Campus Martinsried-Grosshadern, LMU Munich, Munich, Germany.
- Department of Neurology and Stroke, and Hertie Institute for Clinical Brain Research, University of Tübingen, Tübingen, Germany.
| |
Collapse
|
28
|
Yongky A, Lee J, Le T, Mulukutla BC, Daoutidis P, Hu WS. Mechanism for multiplicity of steady states with distinct cell concentration in continuous culture of mammalian cells. Biotechnol Bioeng 2015; 112:1437-45. [PMID: 25676211 DOI: 10.1002/bit.25566] [Citation(s) in RCA: 14] [Impact Index Per Article: 1.6] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/20/2014] [Revised: 02/03/2015] [Accepted: 02/05/2015] [Indexed: 11/09/2022]
Abstract
Continuous culture for the production of biopharmaceutical proteins offers the possibility of steady state operations and thus more consistent product quality and increased productivity. Under some conditions, multiplicity of steady states has been observed in continuous cultures of mammalian cells, wherein with the same dilution rate and feed nutrient composition, steady states with very different cell and product concentrations may be reached. At those different steady states, cells may exhibit a high glycolysis flux with high lactate production and low cell concentration, or a low glycolysis flux with low lactate and high cell concentration. These different steady states, with different cell concentration, also have different productivity. Developing a mechanistic understanding of the occurrence of steady state multiplicity and devising a strategy to steer the culture toward the desired steady state is critical. We establish a multi-scale kinetic model that integrates a mechanistic intracellular metabolic model and cell growth model in a continuous bioreactor. We show that steady state multiplicity exists in a range of dilution rate in continuous culture as a result of the bistable behavior in glycolysis. The insights from the model were used to devise strategies to guide the culture to the desired steady state in the multiple steady state region. The model provides a guideline principle in the design of continuous culture processes of mammalian cells.
Collapse
Affiliation(s)
- Andrew Yongky
- Department of Chemical Engineering and Materials Science, University of Minnesota, Minneapolis, Minnesota
| | - Jongchan Lee
- Department of Chemical Engineering and Materials Science, University of Minnesota, Minneapolis, Minnesota
| | - Tung Le
- Department of Chemical Engineering and Materials Science, University of Minnesota, Minneapolis, Minnesota
| | - Bhanu Chandra Mulukutla
- Department of Chemical Engineering and Materials Science, University of Minnesota, Minneapolis, Minnesota
| | - Prodromos Daoutidis
- Department of Chemical Engineering and Materials Science, University of Minnesota, Minneapolis, Minnesota
| | - Wei-Shou Hu
- Department of Chemical Engineering and Materials Science, University of Minnesota, Minneapolis, Minnesota.
| |
Collapse
|
29
|
Ivarsson M, Noh H, Morbidelli M, Soos M. Insights into pH-induced metabolic switch by flux balance analysis. Biotechnol Prog 2015; 31:347-57. [PMID: 25906421 DOI: 10.1002/btpr.2043] [Citation(s) in RCA: 41] [Impact Index Per Article: 4.6] [Reference Citation Analysis] [Abstract] [Key Words] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/15/2014] [Revised: 11/19/2014] [Indexed: 11/08/2022]
Abstract
Lactate accumulation in mammalian cell culture is known to impede cellular growth and productivity. The control of lactate formation and consumption in a hybridoma cell line was achieved by pH alteration during the early exponential growth phase. In particular, lactate consumption was induced even at high glucose concentrations at pH 6.8, whereas highly increased production of lactate was obtained at pH 7.8. Consequently, constraint-based metabolic flux analysis was used to examine pH-induced metabolic states in the same growth state. We demonstrated that lactate influx at pH 6.8 led cells to maintain high fluxes in the TCA cycle and malate-aspartate shuttle resulting in a high ATP production rate. In contrast, under increased pH conditions, less ATP was generated and different ATP sources were utilized. Gene expression analysis led to the conclusion that lactate formation at high pH was enabled by gluconeogenic pathways in addition to facilitated glucose uptake. The obtained results provide new insights into the influence of pH on cellular metabolism, and are of importance when considering pH heterogeneities typically present in large scale industrial bioreactors.
Collapse
Affiliation(s)
- Marija Ivarsson
- Dept. of Chemistry and Applied Biosciences, Inst. for Chemical and Bioengineering, ETH Zurich, Zurich, Switzerland
| | | | | | | |
Collapse
|
30
|
Fan Y, Jimenez Del Val I, Müller C, Wagtberg Sen J, Rasmussen SK, Kontoravdi C, Weilguny D, Andersen MR. Amino acid and glucose metabolism in fed-batch CHO cell culture affects antibody production and glycosylation. Biotechnol Bioeng 2014; 112:521-35. [DOI: 10.1002/bit.25450] [Citation(s) in RCA: 128] [Impact Index Per Article: 12.8] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/05/2014] [Revised: 08/12/2014] [Accepted: 09/05/2014] [Indexed: 12/12/2022]
Affiliation(s)
- Yuzhou Fan
- Network Engineering of Eukaryotic Cell Factories; Department of Systems Biology; Technical University of Denmark; Building 223 2800 Kgs Lyngby Denmark
- Symphogen A/S; Pederstrupvej 93; 2750 Ballerup Denmark
| | - Ioscani Jimenez Del Val
- Center for Process Systems Engineering; Department of Chemical Engineering; Imperial College London; London UK
| | | | | | | | - Cleo Kontoravdi
- Center for Process Systems Engineering; Department of Chemical Engineering; Imperial College London; London UK
| | | | - Mikael Rørdam Andersen
- Network Engineering of Eukaryotic Cell Factories; Department of Systems Biology; Technical University of Denmark; Building 223 2800 Kgs Lyngby Denmark
| |
Collapse
|
31
|
Hossler P, McDermott S, Racicot C, Chumsae C, Raharimampionona H, Zhou Y, Ouellette D, Matuck J, Correia I, Fann J, Li J. Cell culture media supplementation of uncommonly used sugars sucrose and tagatose for the targeted shifting of protein glycosylation profiles of recombinant protein therapeutics. Biotechnol Prog 2014; 30:1419-31. [DOI: 10.1002/btpr.1968] [Citation(s) in RCA: 18] [Impact Index Per Article: 1.8] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/02/2014] [Revised: 08/04/2014] [Indexed: 12/25/2022]
Affiliation(s)
- Patrick Hossler
- Process Sciences-Cell Culture; AbbVie Inc.; Worcester MA 01605
| | - Sean McDermott
- Process Sciences-Cell Culture; AbbVie Inc.; Worcester MA 01605
| | | | | | | | - Yu Zhou
- Process Sciences-Cell Culture; AbbVie Inc.; Worcester MA 01605
| | - David Ouellette
- Process Sciences-Cell Culture; AbbVie Inc.; Worcester MA 01605
| | - Joseph Matuck
- Process Sciences-Cell Culture; AbbVie Inc.; Worcester MA 01605
| | - Ivan Correia
- Process Sciences-Cell Culture; AbbVie Inc.; Worcester MA 01605
| | - John Fann
- Process Sciences-Cell Culture; AbbVie Inc.; Worcester MA 01605
| | - Jianmin Li
- Oncology Biologics; AbbVie Inc.; Redwood City CA 94063
| |
Collapse
|
32
|
Xu P, Dai XP, Graf E, Martel R, Russell R. Effects of glutamine and asparagine on recombinant antibody production using CHO-GS cell lines. Biotechnol Prog 2014; 30:1457-68. [PMID: 25079388 DOI: 10.1002/btpr.1957] [Citation(s) in RCA: 16] [Impact Index Per Article: 1.6] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/11/2013] [Revised: 07/11/2014] [Indexed: 11/08/2022]
Affiliation(s)
- Ping Xu
- Global Manufacturing and Supply, Bristol-Myers Squibb Company; 519 Route 173 West Bloomsbury NJ 08804
| | - Xiao-Ping Dai
- Global Manufacturing and Supply, Bristol-Myers Squibb Company; 519 Route 173 West Bloomsbury NJ 08804
| | - Erica Graf
- Global Manufacturing and Supply, Bristol-Myers Squibb Company; 519 Route 173 West Bloomsbury NJ 08804
| | - Richard Martel
- Global Manufacturing and Supply, Bristol-Myers Squibb Company; 519 Route 173 West Bloomsbury NJ 08804
| | - Reb Russell
- Global Manufacturing and Supply, Bristol-Myers Squibb Company; 519 Route 173 West Bloomsbury NJ 08804
| |
Collapse
|
33
|
Hakemeyer C, Pech M, Lipok G, Herrmann A. Characterization of the influence of cultivation parameters on extracellular modifications of antibodies during fermentation. BMC Proc 2013. [PMCID: PMC3981685 DOI: 10.1186/1753-6561-7-s6-p85] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/10/2022] Open
|
34
|
Reuel NF, Grassbaugh B, Kruss S, Mundy JZ, Opel C, Ogunniyi AO, Egodage K, Wahl R, Helk B, Zhang J, Kalcioglu ZI, Tvrdy K, Bellisario DO, Mu B, Blake SS, Van Vliet KJ, Love JC, Wittrup KD, Strano MS. Emergent properties of nanosensor arrays: applications for monitoring IgG affinity distributions, weakly affined hypermannosylation, and colony selection for biomanufacturing. ACS NANO 2013; 7:7472-7482. [PMID: 23909808 DOI: 10.1021/nn403215e] [Citation(s) in RCA: 26] [Impact Index Per Article: 2.4] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 06/02/2023]
Abstract
It is widely recognized that an array of addressable sensors can be multiplexed for the label-free detection of a library of analytes. However, such arrays have useful properties that emerge from the ensemble, even when monofunctionalized. As examples, we show that an array of nanosensors can estimate the mean and variance of the observed dissociation constant (KD), using three different examples of binding IgG with Protein A as the recognition site, including polyclonal human IgG (KD μ = 19 μM, σ(2) = 1000 mM(2)), murine IgG (KD μ = 4.3 nM, σ(2) = 3 μM(2)), and human IgG from CHO cells (KD μ = 2.5 nM, σ(2) = 0.01 μM(2)). Second, we show that an array of nanosensors can uniquely monitor weakly affined analyte interactions via the increased number of observed interactions. One application involves monitoring the metabolically induced hypermannosylation of human IgG from CHO using PSA-lectin conjugated sensor arrays where temporal glycosylation patterns are measured and compared. Finally, the array of sensors can also spatially map the local production of an analyte from cellular biosynthesis. As an example, we rank productivity of IgG-producing HEK colonies cultured directly on the array of nanosensors itself.
Collapse
Affiliation(s)
- Nigel F Reuel
- Department of Chemical Engineering, Massachusetts Institute of Technology , Cambridge, Massachusetts 02139, United States
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
35
|
Burnina I, Hoyt E, Lynaugh H, Li H, Gong B. A cost-effective plate-based sample preparation for antibody N-glycan analysis. J Chromatogr A 2013; 1307:201-6. [DOI: 10.1016/j.chroma.2013.07.104] [Citation(s) in RCA: 27] [Impact Index Per Article: 2.5] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/29/2013] [Revised: 07/27/2013] [Accepted: 07/30/2013] [Indexed: 12/26/2022]
|
36
|
Costa AR, Rodrigues ME, Henriques M, Oliveira R, Azeredo J. Glycosylation: impact, control and improvement during therapeutic protein production. Crit Rev Biotechnol 2013; 34:281-99. [PMID: 23919242 DOI: 10.3109/07388551.2013.793649] [Citation(s) in RCA: 104] [Impact Index Per Article: 9.5] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/31/2022]
Abstract
The emergence of the biopharmaceutical industry represented a major revolution for modern medicine, through the development of recombinant therapeutic proteins that brought new hope for many patients with previously untreatable diseases. There is a ever-growing demand for these therapeutics that forces a constant technological evolution to increase product yields while simultaneously reducing costs. However, the process changes made for this purpose may also affect the quality of the product, a factor that was initially overlooked but which is now a major focus of concern. Of the many properties determining product quality, glycosylation is regarded as one of the most important, influencing, for example, the biological activity, serum half-life and immunogenicity of the protein. Consequently, monitoring and control of glycosylation is now critical in biopharmaceutical manufacturing and a requirement of regulatory agencies. A rapid evolution is being observed in this context, concerning the influence of glycosylation in the efficacy of different therapeutic proteins, the impact on glycosylation of a diversity of parameters/processes involved in therapeutic protein production, the analytical methodologies employed for glycosylation monitoring and control, as well as strategies that are being explored to use this property to improve therapeutic protein efficacy (glycoengineering). This work reviews the main findings on these subjects, providing an up-to-date source of information to support further studies.
Collapse
Affiliation(s)
- Ana Rita Costa
- IBB - Institute for Biotechnology and Bioengineering, Centre of Biological Engineering, University of Minho, Campus de Gualtar , Braga , Portugal
| | | | | | | | | |
Collapse
|
37
|
Grainger RK, James DC. CHO cell line specific prediction and control of recombinant monoclonal antibodyN-glycosylation. Biotechnol Bioeng 2013; 110:2970-83. [DOI: 10.1002/bit.24959] [Citation(s) in RCA: 78] [Impact Index Per Article: 7.1] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/28/2013] [Revised: 04/30/2013] [Accepted: 05/06/2013] [Indexed: 12/20/2022]
Affiliation(s)
- Rhian K. Grainger
- ChELSI Institute, Department of Chemical and Biological Engineering; University of Sheffield; Mappin Street Sheffield S1 3JD UK
| | - David C. James
- ChELSI Institute, Department of Chemical and Biological Engineering; University of Sheffield; Mappin Street Sheffield S1 3JD UK
| |
Collapse
|
38
|
Costa AR, Withers J, Rodrigues ME, McLoughlin N, Henriques M, Oliveira R, Rudd PM, Azeredo J. The impact of cell adaptation to serum-free conditions on the glycosylation profile of a monoclonal antibody produced by Chinese hamster ovary cells. N Biotechnol 2013; 30:563-72. [DOI: 10.1016/j.nbt.2012.12.002] [Citation(s) in RCA: 17] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/04/2012] [Revised: 12/03/2012] [Accepted: 12/04/2012] [Indexed: 11/29/2022]
|
39
|
Read EK, Bradley SA, Smitka TA, Agarabi CD, Lute SC, Brorson KA. Fermentanomics informed amino acid supplementation of an antibody producing mammalian cell culture. Biotechnol Prog 2013; 29:745-53. [PMID: 23606649 DOI: 10.1002/btpr.1728] [Citation(s) in RCA: 36] [Impact Index Per Article: 3.3] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/11/2012] [Revised: 03/07/2013] [Indexed: 01/23/2023]
Abstract
Fermentanomics, or a global understanding of a culture state on the molecular level empowered by advanced techniques like NMR, was employed to show that a model hybridoma culture supplied with glutamine and glucose depletes aspartate, cysteine, methionine, tryptophan, and tyrosine during antibody production. Supplementation with these amino acids prevents depletion and improves culture performance. Furthermore, no significant changes were observed in the distribution of glycans attached to the IgG3 in cultures supplemented with specific amino acids, arguing that this strategy can be implemented without fear of impact on important product quality attributes. In summary, a targeted strategy of quantifying media components and designing a supplementation strategy can improve bioprocess cell cultures when enpowered by fermentanomics tools.
Collapse
Affiliation(s)
- Erik K Read
- Div. of Monoclonal Antibodies, CDER, FDA, Silver Spring, MD, USA
| | | | | | | | | | | |
Collapse
|
40
|
Effect of culture pH on recombinant antibody production by a new human cell line, F2N78, grown in suspension at 33.0 °C and 37.0 °C. Appl Microbiol Biotechnol 2013; 97:5283-91. [DOI: 10.1007/s00253-013-4849-2] [Citation(s) in RCA: 18] [Impact Index Per Article: 1.6] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/09/2012] [Revised: 03/07/2013] [Accepted: 03/13/2013] [Indexed: 11/25/2022]
|
41
|
Applying quality by design to glycoprotein therapeutics: experimental and computational efforts of process control. ACTA ACUST UNITED AC 2013. [DOI: 10.4155/pbp.13.4] [Citation(s) in RCA: 18] [Impact Index Per Article: 1.6] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/17/2022]
|
42
|
Cai Z, Fu T, Nagai Y, Lam L, Yee M, Zhu Z, Zhang H. scFv-based "Grababody" as a general strategy to improve recruitment of immune effector cells to antibody-targeted tumors. Cancer Res 2013; 73:2619-27. [PMID: 23396586 DOI: 10.1158/0008-5472.can-12-3920] [Citation(s) in RCA: 13] [Impact Index Per Article: 1.2] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/17/2022]
Abstract
Recruitment of immune cells to tumor cells targeted by a therapeutic antibody can heighten the antitumor efficacy of the antibody. For example, p185(her2/neu)-targeting antibodies not only downregulate the p185(her2/neu) kinase (ERBB2) but also trigger complement-dependent cytotoxicity (CDC) and antibody-dependent cellular cytotoxicity (ADCC) through the antibody Fc region. Here, we describe a generalized strategy to improve immune cell recruitment to targeted cancer cells, using a modified scFv antibody we call a "Grababody" that binds the target protein and endogenous immunoglobulins. The model system we used to illustrate the use of this platform recognizes p185(her2/neu) and includes an IgG binding domain. The recombinant scFv Grababody that was created recruited circulating human IgGs and attracted immune cells carrying Fc receptors to tumor cells that expressed p185(her2/neu). The presence of the IgG binding domain significantly enhanced CDC and ADCC activity and improved antitumor activity in vivo. Our results illustrate a novel general approach to improve antibody-like proteins for therapeutic applications.
Collapse
Affiliation(s)
- Zheng Cai
- Department of Pathology and Lab Medicine, University of Pennsylvania Perelman School of Medicine, Philadelphia, PA, USA
| | | | | | | | | | | | | |
Collapse
|
43
|
Zhu J. Mammalian cell protein expression for biopharmaceutical production. Biotechnol Adv 2012; 30:1158-70. [PMID: 21968146 DOI: 10.1016/j.biotechadv.2011.08.022] [Citation(s) in RCA: 319] [Impact Index Per Article: 26.6] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/29/2011] [Revised: 08/26/2011] [Accepted: 08/29/2011] [Indexed: 12/13/2022]
|
44
|
Kou TC, Fan L, Zhou Y, Ye ZY, Zhao L, Tan WS. Increasing the productivity of TNFR-Fc in GS-CHO cells at reduced culture temperatures. BIOTECHNOL BIOPROC E 2011. [DOI: 10.1007/s12257-010-0157-1] [Citation(s) in RCA: 6] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/18/2022]
|
45
|
Gramer MJ, Eckblad JJ, Donahue R, Brown J, Shultz C, Vickerman K, Priem P, van den Bremer ETJ, Gerritsen J, van Berkel PHC. Modulation of antibody galactosylation through feeding of uridine, manganese chloride, and galactose. Biotechnol Bioeng 2011; 108:1591-602. [PMID: 21328321 DOI: 10.1002/bit.23075] [Citation(s) in RCA: 136] [Impact Index Per Article: 10.5] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/28/2010] [Revised: 12/15/2010] [Accepted: 01/18/2011] [Indexed: 12/20/2022]
Abstract
Through process transfer and optimization for increased antibody production to 3 g/L for a GS-CHO cell line, an undesirable drop in antibody Fc galactosylation was observed. Uridine (U), manganese chloride (M), and galactose (G), constituents involved in the intracellular galactosylation process, were evaluated in 2-L bioreactors for their potential to specifically increase antibody galactosylation. These components were placed in the feed medium at proportionally increasing concentrations from 0 to 20 × UMG, where a 1× concentration of U was 1 mM, a 1× concentration of M was 0.002 mM, and a 1× concentration of G was 5 mM. Antibody galactosylation increased rapidly from 3% at 0× UMG up to 21% at 8× UMG and then more slowly to 23% at 20× UMG. The increase was primarily due to a shift from G0F to G1F, with minimal impact on other glycoforms or product quality attributes. Cell culture performance was largely not impacted by addition of up to 20× UMG except for suppression of glucose consumption and lactate production at 16 and 20× UMG and a slight drop in antibody concentration at 20× UMG. Higher accumulation of free galactose in the medium was observed at 8× UMG and above, coincident with achieving the plateau of maximal galactosylation. A concentration of 4× UMG resulted in achieving the target of 18% galactosylation at 2-L scale, a result that was reproduced in a 1,000-L run. Follow-up studies to evaluate the addition of each component individually up to 12× concentration revealed that the effect was synergistic; the combination of all three components gave a higher level of galactosylation than addition of the each effect independently. The approach was found generally useful since a second cell line responded similarly, with an increase in galactosylation from 5% to 29% from 0 to 8× UMG and no further increase or impact on culture performance up to 12× UMG. These results demonstrate a useful approach to provide exact and specific control of antibody galactosylation through manipulation of the concentrations of uridine, manganese chloride, and galactose in the cell culture medium.
Collapse
Affiliation(s)
- Michael J Gramer
- Genmab MN, Inc., 9450 Winnetka Ave N, Brooklyn Park, Minnesota 55445, USA.
| | | | | | | | | | | | | | | | | | | |
Collapse
|
46
|
Müller-Späth T, Krättli M, Aumann L, Ströhlein G, Morbidelli M. Increasing the activity of monoclonal antibody therapeutics by continuous chromatography (MCSGP). Biotechnol Bioeng 2011; 107:652-62. [PMID: 20589849 DOI: 10.1002/bit.22843] [Citation(s) in RCA: 77] [Impact Index Per Article: 5.9] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/01/2023]
Abstract
The charged monoclonal antibody (mAb) variants of the commercially available therapeutics Avastin®, Herceptin® and Erbitux® were separated by ion-exchange gradient chromatography in batch and continuous countercurrent mode (MCSGP process). Different stationary phases, buffer conditions and two MCSGP configurations were used in order to demonstrate the broad applicability of MCSGP in the field of charged protein variant separation. Batch chromatography and MCSGP were compared with respect to yield, purity, and productivity. In the case of Herceptin®, also the biological activity of the product stream was taken into account as performance indicator. The robustness of the MCSGP process against feed composition variations was confirmed experimentally and by model simulations.
Collapse
Affiliation(s)
- T Müller-Späth
- Institute for Chemical and Bioengineering, ETH Zurich, Wolfgang-Pauli-Strasse 10, Zurich, Switzerland
| | | | | | | | | |
Collapse
|
47
|
Hossler P. Protein glycosylation control in mammalian cell culture: past precedents and contemporary prospects. ADVANCES IN BIOCHEMICAL ENGINEERING/BIOTECHNOLOGY 2011; 127:187-219. [PMID: 22015728 DOI: 10.1007/10_2011_113] [Citation(s) in RCA: 18] [Impact Index Per Article: 1.4] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 12/20/2022]
Abstract
Protein glycosylation is a post-translational modification of paramount importance for the function, immunogenicity, and efficacy of recombinant glycoprotein therapeutics. Within the repertoire of post-translational modifications, glycosylation stands out as having the most significant proven role towards affecting pharmacokinetics and protein physiochemical characteristics. In mammalian cell culture, the understanding and controllability of the glycosylation metabolic pathway has achieved numerous successes. However, there is still much that we do not know about the regulation of the pathway. One of the frequent conclusions regarding protein glycosylation control is that it needs to be studied on a case-by-case basis since there are often conflicting results with respect to a control variable and the resulting glycosylation. In attempts to obtain a more multivariate interpretation of these potentially controlling variables, gene expression analysis and systems biology have been used to study protein glycosylation in mammalian cell culture. Gene expression analysis has provided information on how glycosylation pathway genes both respond to culture environmental cues, and potentially facilitate changes in the final glycoform profile. Systems biology has allowed researchers to model the pathway as well-defined, inter-connected systems, allowing for the in silico testing of pathway parameters that would be difficult to test experimentally. Both approaches have facilitated a macroscopic and microscopic perspective on protein glycosylation control. These tools have and will continue to enhance our understanding and capability of producing optimal glycoform profiles on a consistent basis.
Collapse
Affiliation(s)
- Patrick Hossler
- Abbott Laboratories, Abbott Bioresearch Center, Worcester, MA, 01605, USA,
| |
Collapse
|
48
|
|
49
|
del Val IJ, Kontoravdi C, Nagy JM. Towards the implementation of quality by design to the production of therapeutic monoclonal antibodies with desired glycosylation patterns. Biotechnol Prog 2010; 26:1505-27. [DOI: 10.1002/btpr.470] [Citation(s) in RCA: 107] [Impact Index Per Article: 7.6] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/02/2023]
|
50
|
Borys MC, Dalal NG, Abu-Absi NR, Khattak SF, Jing Y, Xing Z, Li ZJ. Effects of culture conditions onN-glycolylneuraminic acid (Neu5Gc) content of a recombinant fusion protein produced in CHO cells. Biotechnol Bioeng 2010; 105:1048-57. [DOI: 10.1002/bit.22644] [Citation(s) in RCA: 20] [Impact Index Per Article: 1.4] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/21/2022]
|